RxDoctor Payments Data

Gordon Long, MD

Family Medicine · Ontario, OHNPI 1487769766

Payments from drug & device makers

$11,080in general payments, 2019–2025

Across 744 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$830
  • Pfizer$566
  • Lilly USA, LLC$462
  • GSK$457
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$11,02199%
  • Education$581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,080 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$28,193
Medicare patients
257
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$105,060
EliquisApixaban71$74,283
JardianceEmpagliflozin46$63,124
RexultiBrexpiprazole35$56,257
TrulicityDulaglutide43$54,083
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$45,234
FarxigaDapagliflozin Propanediol32$41,402
CreonLipase/Protease/Amylase14$36,916
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$33,330
Humalog Kwikpen U-200Insulin Lispro14$29,189
ProliaDenosumab16$27,758
MounjaroTirzepatide16$25,450
Tresiba Flextouch U-100Insulin Degludec42$22,317
LinzessLinaclotide22$21,497
XareltoRivaroxaban13$20,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,161$105,06088 claims
Lilly USA, LLCTrulicity, Mounjaro$462$79,53359 claims
PfizerEliquis$566$74,28371 claims
Boehringer IngelheimJardiance$301$63,12446 claims
AbbVieCreon, Linzess$2,322$58,41336 claims
Otsuka America Pharmaceutical, Inc.Rexulti$374$56,25735 claims
AstraZenecaFarxiga, Breztri Aerosphere$830$51,40548 claims
GSKTrelegy Ellipta$457$33,33042 claims
AmgenProlia$306$27,75816 claims
MerckJanuvia, Belsomra$290$21,28629 claims
Johnson & JohnsonXarelto$443$20,47413 claims
NovartisEntresto$182$19,37914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Ontario

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →